 DELRAY BEACH, Fla., Jan. 28, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. AzurRx or the Company NASDAQ: AZRX, a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal GI diseases, today announced the completion of patient enrollment in the first cohort of the Phase 2b OPTION 2 extension study evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency EPI in patients with cystic fibrosis CF. 